The objective of the present study is to identify novel myokines, expression of which is altered in skeletal muscle after a single bout of exercise.
ID
Source
Brief title
Condition
- Glucose metabolism disorders (incl diabetes mellitus)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Main study outcomes include upregulation of genes in skeletal muscle after
exercise (with a focus on genes encoding myokines) and changes of blood plasma
levels of selected proteins after exercise. The proteins are selected based on
gene expression changes measured.
Secondary outcome
PBMC gene expression: gene expression changes in the blood will be assessed
Routine plasma levels: plasma levels of glucose, insulin, fatty acids,
cortisol, adrenalin and lactate will be determined.
Heart rate: heart rate will be measured.
Background summary
Proteins released from muscle during and shortly after exercise, often referred
to as myokines, may be central to our understanding of the cross-talk during
and after exercise between skeletal muscles and other organs, in particular the
liver. So far only a few myokines are identified (e.g. IL-6, IL-8, IL-15,
TNF-alpha). Taking into account the role of these several known myokines in
developing insulin resistance, revealing new putative myokines might provide
valuable information for the treatment and prevention of type 2 diabetes.
Study objective
The objective of the present study is to identify novel myokines, expression of
which is altered in skeletal muscle after a single bout of exercise.
Study design
This is an experimental study.
Intervention
The intervention is a single exercise bout that consists of one hour one-legged
cycling on a adapted recumbent cycle ergometer at a submaximal rate. The
non-exercising leg will serve as control for the exercising leg.
Study burden and risks
During the screening session, blood pressure, height and weight will be
measured and a medical questionnaire will be filled in. The two familiarization
trails consist of 20 minutes of one-legged cycling on a low work load. The
preliminary testing has two parts, a maximum work load test and a maximum
oxygen uptake test. Both tests are graded exercise tests to exhaustion. During
both tests, heart rate is measured non-invasively and during the maximum oxygen
test oxygen uptake is measured non-invasively. The experimental session
consists of an one hour exercising period at a submaximal rate. Subjects will
cycle with their dominant leg on an adapted recumbent cycle ergometer. Before
(T = 0) and after the exercise period (T = 1) muscle biopsies will be taken
from both legs. At T = 0, T = 1 and after 2 hours of rest (T= 3), venous blood
samples will be obtained. Heart rate will be measured non-invasively. Prior to
the experimental session participants are asked to refrain from alcohol and
heavy exercise respectively one day and one week before the session, arrive in
a fasted state, eat a prescribed dinner the evening before the session.
The time investment requested from the participants is 1 hour at the
information meeting, 1.0 hour at a screening session, 2 x 1.0 hours at the
familiarization trails, 2,5 hours at the preliminary testing and 5 hours for
the experimental session. In total this is an investment of 11.5 hours.
Risks for the subjects during this study are considered low. Muscle biopsies
will be taken by an experience physician, and proper precautions will be taken
to minimize the risk of complications. Taking a muscle biopsy can generate mild
discomfort and result in local bruising. To minimize this risk a pressure
bandage will be applied. Venous blood samples can occasionally cause a local
haematoma or bruise and some participants may report pain or discomfort. The
exercise sessions during this study, in particular the graded exercise tests
(one- and two-legged) and the experimental task may induce muscle soreness.
This is harmless and disappears after a few days, but it may cause an
uncomfortable feeling.
The participant will not have any health-related benefits from this research,
but will receive a monetary reward.
Dreijenlaan 2
6703 HA Wageningen
NL
Dreijenlaan 2
6703 HA Wageningen
NL
Listed location countries
Age
Inclusion criteria
• Age 40-60 years
• Male gender
• BMI < 30 kg/m2
Exclusion criteria
• Exercising regularly (> 2 times a week, > 3 hour in total per week)
• Unstable body weight (weight gain or loss > 3 kg in the past three months)
• Following, or have recently followed a (weight-loss) diet
• Donated or intended to donate blood 2 months before until two months after the study
• Medical condition that can interfere with the study outcome (i.e. cardiovascular disease, pulmonary disease)
• Systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg
• Use of medications known to interfere with gene expression in the muscles (i.e. statins, fenofibrate)
• Use of antithrombotic therapy (marcoumar, sintromitis).
• Diagnosed diabetes mellitus type 1 or 2.
• Drugs or alcohol abuse ( > 3 glasses of alcoholic beverages a day).
• (Chronic) injuries of the locomotor system that can interfere with the intervention
• Participated in another study within the last six months
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL33968.081.10 |